Mylan has struck a deal to commercialize Lupin's biosimilar Enbrel (etanercept), continuing to seize opportunities beyond existing alliances to ensure an early play in certain key markets. Longstanding Mylan partner Biocon maintains that it won't lose out either, though the outlook for their partnered etanercept is unclear, at least for now.
MYLAN IS KEEN TO GET ITS MARKET TIMING RIGHT FOR KEY BIOSIMILARS
Mylan NV is leap-frogging plans for biosimilar etanercept in certain key markets via an alliance with Lupin, along the lines of similar efforts for biosimilar adalimumab earlier this year.
The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.
The weak US dollar helped some companies reporting first-quarter results and hindered others reporting in stronger currencies. But even the impacts of currencies and Medicare modernization on first-quarter revenues were overlooked when an end to the trade wars seemed possible.
In this week's episode: AstraZeneca CEO cautions Europe; Pfizer CEO optimistic on US tariffs, pricing; Merck & Co reassures on pipeline; Merck KGaA buys SpringWorks; and Akeso explains ivonescimab overall survival data.
Vertex is in need of diversification, but in addition to its lower-than-expected Q1 revenue, sales of the company’s newest CF drug Alyftrek and pain medicine Journavx disappointed.
Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.
In this week's episode: AstraZeneca CEO cautions Europe; Pfizer CEO optimistic on US tariffs, pricing; Merck & Co reassures on pipeline; Merck KGaA buys SpringWorks; and Akeso explains ivonescimab overall survival data.